Precision Medicine

Arcturus Therapeutics heads to the Canaccord Growth Conference to spotlight its advanced mRNA platform, shifting focus from COVID vaccines to rare diseases.

Precision IO Group is showcasing its AI-guided Epione robot and a vision for remote cancer surgery, aiming to erase geographic barriers to expert care.

A single-collimator system that images all isotopes is more than an upgrade; it's a strategic move to dominate the future of personalized cancer care.

IntelliGenome's revolutionary CRISPR-TB diagnostic arrives in South Africa via a key partnership, offering a new, blood-based tool to tackle the TB crisis.

With FDA Fast Track and a key ESMO presentation, Nouscom is de-risking its pioneering cancer interception therapy, NOUS-209, for Lynch Syndrome.

Lundbeck completes enrollment for a pivotal trial testing a novel drug for severe childhood epilepsies. But what are the real stakes for patients and investors?

A novel AI-designed drug that can cross the formidable blood-brain barrier has entered U.S. trials, targeting some of the deadliest brain tumors.

Aptorum Group is transforming into Niki BioSolutions after its merger with DiamiR, betting its future on innovative microRNA blood tests for brain health.

EHE Health is now offering GRAIL's Galleri test, a move that signals a major shift in corporate wellness but raises key questions about cost and access.

A new biotech collaboration aims to accelerate a novel diagnostic platform, highlighting a growing trend of outsourcing operations to speed innovation in precision medicine.

A groundbreaking NEJM report shows Neutrolis's therapy rapidly reversed severe Lupus symptoms, validating a new, non-immunosuppressive approach.

Parse Biosciences, QIAGEN's strategic acquisition, just partnered with Australia's Garvan Institute. It's more than science—it's a calculated play to win.

A new partnership between Nouveau Biosciences and Anova aims to fast-track a novel nanomedicine, offering a beacon of hope for patients with aggressive lymphomas.

Bruker's acquisition of the DISQVER® platform signals a major shift in infection diagnostics, promising to identify thousands of pathogens in hours, not days.

Proteomics firm Genopore hires a proven growth architect, Rey Mali. Can her commercial savvy finally democratize protein sequencing and capture a $60B market?

A new Long Island spine center isn't just offering advanced surgery; it's pioneering a 'boutique' model that merges high-tech robotics with high-touch service, rewriting the rules for patient care.

The launch of LacP™ isn't just a new test; it's a strategic move into the high-growth femtech diagnostics space, shifting the focus from reaction to prevention.

Kura Oncology's upcoming kidney cancer data is just the tip of the iceberg. A closer look reveals a strategic play to make darlifarnib a universal partner drug.

A new $4,000-a-year service combines genomics and AI for proactive health. But as SONATA launches, it exposes the deep divide in our digital future.

Atrium Therapeutics' clinical trial for a rare cardiomyopathy isn't just a milestone; it's a strategic maneuver signaling the arrival of precision RNA therapies in cardiology.